Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party.
AffiliationMedical Research Council Cancer Trials Office, Cambridge, UK.
MetadataShow full item record
AbstractOBJECTIVES: This paper investigates the problem of treatment-related deaths in small cell lung cancer (SCLC). DESIGN: To observe and define increased hazard levels, and to identify factors relating to these excess deaths. SETTING: The United Kingdom. SUBJECTS: A total of 2196 patients entered into the series of six randomised clinical trials in SCLC conducted by the Medical Research Council (MRC) Lung Cancer Working Party (LCWP). RESULTS: In this large series of patients an increased risk of death in the second week after commencing the first cycle of chemotherapy was observed, suggesting that of the 10% of patients who died within 3 weeks of starting chemotherapy, half may have been treatment-related. Much less additional risk was associated with subsequent cycles of chemotherapy, and no additional risk with either initial surgery or radiotherapy. Radford et al. [Eur J Cancer 1993; 29A: 81-86] suggested that the risk factors for death from sepsis were a Karnofsky Performance (KP) score of < or = 50 (translated as a WHO performance grade (PS) > or = 3), age > 50 years and three or more drugs in the chemotherapy regimen utilised. Starting with this model we found that our data suggest it can be refined by omitting age and including a white blood cell count > or = 10,000/mm3 (this variable was not tested by Radford), and changing the other categories to WHO PS > or = 2 (KP < or = 70), and four or more drugs. Within our data this revised model identified a high risk group of patients with an excess death rate of more than 15% in the second week after starting chemotherapy. Radford et als' suggestion that high risk patients be given half doses of drugs at the first cycle should be tested in a randomised clinical trial.
CitationTreatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. 1994, 11 (3-4):259-74 Lung Cancer
- Long-term survival in small cell lung cancer: the case for a standard definition. Medical Research Council Lung Cancer Working Party.
- Authors: Stephens RJ, Bailey AJ, Machin D
- Issue date: 1996 Nov
- Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.
- Authors: Bleehen NM, Girling DJ, Gregor A, Leonard RC, Machin D, McKenzie CG, Morgan DA, Smyth JF, Spittle MF, Stephens RJ
- Issue date: 1994 Jul
- A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
- Authors: Bleehen NM, Girling DJ, Machin D, Stephens RJ
- Issue date: 1993 Dec
- Does clinical experience with a treatment regimen affect survival of lung cancer patients? An analysis based on consecutive randomized trials of the Medical Research Council in small cell and non-small cell tumours. Medical Research Council Lung Cancer Working Party.
- Authors: Wheeler JG, Machin D, Campbell MJ, Stephens RJ, Bleehen NM, Girling DJ
- Issue date: 1994
- A simulated sequential analysis based on data from two MRC trials.
- Authors: Donaldson AN, Whitehead J, Stephens R, Machin D
- Issue date: 1993 Dec